NYXH Nyxoah

Publication Relating to a Transparency Notification

Publication Relating to a Transparency Notification

                

REGULATED INFORMATION

Publication Relating to a Transparency Notification

Mont-Saint-Guibert (Belgium), July 27, 2023, 10.30pm CET / 4.30pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification.

On July 25, 2023, Nyxoah received the rectification of the April 16, 2023 transparency notification that it had received from ResMed Inc. in relation to the upward crossing of the 5% threshold by ResMed Inc. on March 30, 2023. The correction relates to the number of shares and the percentage of voting rights held by ResMed Inc. on March 30, 2023: ResMed Inc. held 1,619,756 shares, representing 5.73% of the total number of voting rights (and not 1,499,756 shares or 5.30% of the voting rights as stated in the April 2023 notification).

The notification dated July 17, 2023 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement: ResMed Inc., 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA
  • Date on which the threshold was crossed: March 30, 2023
  • Threshold that is crossed: 5%
  • Denominator: 28,286,985
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the

securities
Linked to securitiesNot linked to the

securities
ResMed Inc.794,2351,619,756 5.73% 
 TOTAL1,619,756 05.73%0.00%
  • Chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.



*

* *

Contact:

Nyxoah

David DeMartino, Chief Strategy Officer



Attachment



EN
27/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® ...

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage Mont-Saint-Guibert, Belgium – October 6, 2025 7:00 CET / 1:00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the first U.S. commercial patients have been successfully implanted with...

 PRESS RELEASE

Nyxoah Annonce les Premiers Patients Commerciaux Aux États-Unis Implan...

Nyxoah Annonce les Premiers Patients Commerciaux Aux États-Unis Implantés avec le Système Genio® Nyxoah Annonce les Premiers Patients Commerciaux Aux États-Unis Implantés avec le Système Genio® Le lancement commercial initial témoigne d'une forte demande de la part des médecins, de préautorisations concluantes et d'une couverture étendue par les payeurs Mont-Saint-Guibert, Belgique – 6 octobre 2025, 7h00 CET / 1h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires...

 PRESS RELEASE

Publication relating to transparency notifications

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On October 1, 2025, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities or voting r...

 PRESS RELEASE

Publication relative à des notifications de transparence

Publication relative à des notifications de transparence         INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 3 octobre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous. Vestal Point Capital Le 1er octobre 2025, Nyxoah a reçu une notification de transparence de Vestal Point Capital suite à une acquisitio...

 PRESS RELEASE

Nyxoah Provides an Update on Expanded Middle East Presence

Nyxoah Provides an Update on Expanded Middle East Presence Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced the continued expansion of its commercial footprint in the Middle East, following the first successful Genio® implant in A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch